[Is it possible to reduce the number of patients studied in drug tests before the drug tested is authorized for marketing?].
Flamant
R
R
Spriet Consultant, Paris.
Spriet
A
A
Caulin
C
C
Doyon
F
F
Cazor
J L
JL
Jaillon
P
P
D017326:Clinical Trials, Phase III as Topic; D017327:Clinical Trials, Phase IV as Topic; D017277:Drug Approval; D005602:France; D006801:Humans; D007880:Legislation, Drug; D010361:Patients; D014481:United States; D014486:United States Food and Drug Administration
Peut-on diminuer le nombre de patients étudiés avant Autorisation de Mise sur le Marché?